Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound PEG 3350 oral solution vs lactulose for overt hepatic encephalopathy
ChiCTR2500105829Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jul 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of polyethylene glycol 3350 in hepatic encephalopathy (HE) (2 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoint: HESA score improvement at 24 hours. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
polyethylene glycol 3350
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on ChiCTR2500105829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105829.